TWiV 1016: Clinical update with Dr. Daniel Griffin
Episode description
In his weekly clinical update, Dr. Griffin discusses surveillance to track progress toward poliomyelitis eradication, genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3, evaluation of Oseltamivir used to prevent hospitalization in outpatients with Influenza, viral emissions into the air and environment after SARS-CoV-2 human challenge, has COVID-19 threatened routine childhood vaccination, successful treatment of persistent symptomatic COVID-19 infection with extended duration Nirmatrelvir/Ritonavir, anemia as a risk factor for disease progression in patients admitted for COVID-19, impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome, post-COVID condition in patients with inflammatory rheumatic diseases, outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months, metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial, persistent serum protein signatures define an inflammatory subcategory of long COVID, and the relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Surveillance to track progress toward poliomyelitis eradication (CDC)
- Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3 (Nature)
- Evaluation of Oseltamivir to prevent hospitalization in outpatients with Influenza (JAMA)
- Viral emissions into air and environment after SARS-CoV-2 human challenge (The Lancet)
- Has COVID-19 threatened routine childhood vaccination (Health Affairs)
- Successful treatment of COVID-19 with extended duration Nirmatrelvir/Ritonavir (OFID)
- Anemia as a risk factor for disease progression in patients admitted for COVID-19 (Nature)
- Impact of fatigue as the determinant of functional limitations among patients with post-COVID-19 syndrome (BMJ)
- Post-COVID condition in patients with inflammatory rheumatic diseases (The Lancet)
- Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition (The Lancet)
- Metformin reduces SARS-CoV-2 in a Phase 3 placebo controlled clinical trial (MedRxiv)
- Persistent serum protein define an inflammatory subcategory of long COVID (Nature)
- Relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome (JTM)
- Contribute to our FIMRC fundraiser at PWB
- Letters read on TWiV 1016
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv